Del Labs
This article was originally published in The Rose Sheet
Executive Summary
Third quarter net sales rose 4.7% to $99.7 mil., driven by solid performance of the company's core brands, including Sally Hansen, which maintained its top ranking in the mass market nail care category, Del Labs reports in an Oct. 28 release. Sally Hansen has a 26% market share in the segment the company notes, citing ACNielsen figures. Despite strong sales, overall earnings fell 8.7% to $4.7 mil., impacted by higher advertising and display costs primarily associated with the launch of the brand's new Healing Beauty color range, which bowed early in the year (1"The Rose Sheet" Dec. 2, 2002, p. 3)...
You may also be interested in...
Sally Hansen Color Cosmetics Bring Healing Positioning To Category
Del Labs is making a full-scale push into the color cosmetics category in January with the launch of Sally Hansen Healing Beauty, a makeup line with a "good-for-you" positioning, Exec VP-Marketing William McMenemy said
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.